ERBB2 and neoplasm: In addition, we established a new HER2 and PDL1 double positive breast cancer mouse model for the novel purpose of testing anti-tumor effect of CAR-T cells plus anti-PD1 in a complete tumor-immune system microenvironment in vivo.